In conclusion, these studies identify novel biomarkers that can be used to objectively define TERTpWT-IDHWT GBM tumors and have discovered a novel role of somatic SMARCAL1 loss-of-function mutations in the ALT phenotype in human cancers. The gene discussed is SMARCAL1; the disease is glioblastoma.